Skip to Main Content
Wexler Boley & Elgersma LLP
  • Our Firm
    • Who We Serve
      • Shareholders
      • Whistleblowers
      • Consumers
      • Businesses
      • Government Entities
    • Our Professionals
    • Working with Wexler Boley & Elgersma LLP
    • Locations
    • News
    • Careers
    • Report Your Concern
    • Testimonials
  • Practice Areas
    • Antitrust Litigation
    • Business & Commercial Litigation
    • Securities & Corporate Governance
    • Healthcare Litigation
    • Consumer Protection
    • Whistle Blower False Claims Litigation
    • Government Representation
    • Employment Litigation
  • Cases
    • Antitrust Litigation Cases
    • Business & Commercial Litigation Cases
    • Consumer Protection Cases
    • Employment Litigation Cases
    • Government Representation Cases
    • Healthcare Litigation Cases
    • Mass Tort Litigation Cases
    • Securities & Corporate Governance Cases
    • Whistle Blower False Claims Cases
  • Investigations
    • Similac Toxic Infant Formula Lawsuit
    • Kid’s Castle Biometric Privacy Lawsuit
    • Contaminated Baby Food Lawsuit
    • Fatal Sportmix Pet Food Recall Class Action Lawsuit
    • Claire’s Data Breach Lawsuit
    • Insurance Denial for Mental Health and Substance Abuse Treatment
    • Perpetual Sales Litigation
    • Railroad Price-Fixing Lawsuit
    • Medicare Advantage Fraud Litigation
    • Biometric Fingerprinting Litigation
  • Blog
  • Contact Us
See all news
11.9.2017

Court Grants Class Certification, Denies Defendant Summary Judgement in Asacol Antitrust Lawsuit

On Thursday, November 9th, the Hon. Judge Denise J. Casper of the United States District Court District of Massachusetts issued an opinion granting the Plaintiffs’ motion for class certification in the case of In re: Asacol Antitrust Litigation, Case No.: 1:15-cv-12730-DJC.

Judge Casper also denied the Defendants’ motion for summary judgement, defeating their claim that pulling its ulcerative colitis drug off the market shortly before patent expiration cannot be considered anti-competitive conduct.

Warner Chilcott, the Allergan subsidiary and manufacturer of Asacol, is accused of using an alleged unlawful anticompetitive “product hop” scheme to prevent a generic version of Asacol 400mg from reaching the market, thus preserving its monopoly profits on a “new” patent-protected drug—Delzicol.

Plaintiffs in this case are represented by Wexler Wallace LLP, Wagstaff & Cartmell LLP, Gustafson Gluek PLLC, and others.

Share

  • Facebook
  • Twitter
  • LinkedIn
Image

311 S. Wacker Drive,
Suite 5450
Chicago, IL 60606
P_312.346.2222
F_312.346.0022

  • Our Firm
  • Practice Areas
  • Cases
  • Investigations
  • Newsroom
  • Blog
  • Contact Us
  • Sitemap
  • Privacy Statement
  • Legal Disclaimer

2022 © Wexler Boley & Elgersma LLP